Contineum Therapeutics CTNM
NASDAQ CTNM
$10.77 +0.21 (+1.99%)
At close: Nov 11, 2026 · 4:00 PM EST

Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Updated

Contineum Therapeutics (CTNM) reported EBITDA Margin of 32.16% for FY2023.

Analysis

Contineum Therapeutics (CTNM) EBITDA Margin (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Contineum Therapeutics 405.40 Mn -584.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 77.51%
API Access

Contineum Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=CTNM&period=max&api_key=YOUR_API_KEY